Form 4: Janux Therapeutics Director Ronald Barrett Granted Significant Equity Awards

Janux Therapeutics, Inc. Director Ronald W. Barrett was granted 3,750 restricted stock units and options to purchase 11,667 shares of common stock on June 11, 2025, as part of his compensation.

Summary

• Ronald W. Barrett, a Director of Janux Therapeutics, Inc. (JANX), was granted equity awards on June 11, 2025.
• The awards include 3,750 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs will vest on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, contingent on Mr. Barrett's continuous service.
• Additionally, Mr. Barrett was granted options to purchase 11,667 shares of common stock.
• The exercise price for these stock options is $25.46 per share, and they expire on June 10, 2035.
• The stock options will vest in equal monthly installments over 12 months following June 11, 2025, or fully vest on the date of the next annual meeting, subject to continuous service.
• Following these transactions, Mr. Barrett beneficially owns 6,250 shares of common stock directly and 11,667 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally positive as it aligns management's interests with shareholders, incentivizing long-term performance. It's a routine compensation event, not indicative of specific operational or financial performance, hence a moderately positive score.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of shareholders, incentivizing long-term value creation.
• The equity awards serve as a form of compensation, retaining experienced leadership within the company.

Future Outlook

The vesting schedules for the granted RSUs and stock options extend into 2026 and 2035, respectively, contingent on the director's continuous service, indicating a long-term incentive structure.

Industry Context

This filing represents a routine compensation event for a director in a publicly traded biotechnology company, common practice to align executive and board interests with shareholder value.

Related Party Transactions

• The transaction involves the grant of equity awards to Ronald W. Barrett, a Director of Janux Therapeutics, Inc., which constitutes a related party transaction as it is compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The equity grant aims to align the director's long-term interests with shareholder value creation.
• Director (Ronald W. Barrett): Receives significant equity compensation, increasing his stake and potential future wealth tied to the company's performance.

Next Steps

• Vesting of 3,750 Restricted Stock Units on the earlier of June 11, 2026, or the next annual meeting of stockholders.
• Monthly vesting of 11,667 stock options over 12 months following June 11, 2025, or full vesting on the next annual meeting of stockholders.

Key Dates

Keywords

Janux Therapeutics, JANX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership